Her-2/Neu IHC (gastric)
Alternative name:
HER2
Methodology
Immunohistochemistry (IHC)
Test Description and clinical significance
Disease:
breast, ovarian, bladder, pancreatic, and stomach cancers
Measures the amount of HER2/neu protein on cancer cells or how many copies of the HER2/neu gene are in the DNA of cancer cells. The HER2/neu protein helps control normal cell growth. Larger than normal amounts of the HER2/neu protein or too many copies of the HER2/neu gene may be made by some types of cancers. HER-2/neu is the most important amplified oncogene in gastric cancer. determination of HER2 status is crucial in order to select patients with advanced gastric cancer who may benefit from HER2 molecular targeted therapy. IHC should be used as the first screening method for HER2 evaluation and those cases with results considered equivocal for HER2 overexpression (2+) should be referred for FISH analysis or other alternative in situ hybridization method
Specimen Requirements
Collection:
FFPE/un-stained slides/Fresh tissue in formalin
Stability:
Room temperature
Unacceptable Conditions:
Unlabeled specimen/specimen left unfixed for extended periods
Storage & Transport
Room Temperature
CPT(s)
88360
New York Approved
YES
TAT
1 Day
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
